4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Adenocarcinoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 864 ongoing clinical trials involving Adenocarcinoma
Of the 864 trials,338 trials are in Phase II
Furthermore, 205 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Adenocarcinoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Adenocarcinoma, an Oncology Disorder. The highest number of ongoing clinical trials involving Adenocarcinoma is conducted in the Asia-Pacific region. Europe and North America are among some of the other prominent regions involved in Adenocarcinoma-related drug trials.

University of Texas MD Anderson Cancer Center: The leading ongoing Adenocarcinoma related clinical trial sponsor

University of Texas MD Anderson Cancer Center, a leading cancer care centers in the US, is the top sponsor for Adenocarcinoma-related ongoing clinical trials.

National Cancer Institute US, Sun Yat-sen University, Memorial Sloan Kettering Cancer Center, and FUDAN University are a few other notable sponsors involved in Adenocarcinoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Adenocarcinoma

Human papillomavirus types L1 proteins 6, 11, 16, and 18 (Gardasil / Silgard), Docetaxel (Taxotere), and Melphalan (Alkeran, Melphalan Hydrochloride) are among the key marketed drugs involving Adenocarcinoma.

Human papillomavirus types L1 proteins 6, 11, 16, and 18 (Gardasil / Silgard) is an adjuvant non-infectious recombinant quadrivalent vaccine acts as immunizing preparation against human papillomavirus. L1 protein in the form of virus-like particles produced in yeast cells (Saccharomyces cerevisiae CANADE 3C-5 (Strain 1895)) by recombinant DNA technology. It is formulated as suspension for injection administered by intramuscular route. Gardasil is marketed for the treatment of Adenocarcinoma and several other indications including Anal Cancer, Squamous Cell Carcinoma, Vaginal Cancer, Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Genital Warts (Condylomata Acuminata), Urethral Cancer, Vulvar Cancer. It was first approved in 2006 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Merck & Co Inc and several other companies including Organon Pharma (UK) Ltd, and MSD Belgium BVBA SPRL.

Docetaxel (Taxotere) is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata, acts as an antineoplastic agent. It functions via Tubulin Inhibitor mechanism of action. It is formulated as injection, solution for concentrate and injection, solution for intravenous route of administration. It is indicated for the treatment of Adenocarcinoma and several other indications including Breast Cancer, Ovarian Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Esophageal Cancer, Head and Neck Cancer, Gastric Cancer, Metastatic Breast Cancer, Endometrial Cancer. It was first approved in 1995 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Sanofi group, and Winthrop US.